89540-41-0

Upstream product

• 15068-35-6 2-chloro-3-methylbenzoic acid 
• 920759-94-0 methyl 3-(bromomethyl)-2-chlorobenzoate 

Downstream Products

• 920759-96-2 C₂₈H₂₇BrClNO₅S 
• 1179338-46-5 3-(carboxymethyl)-2-chlorobenzoic acid 
• 1179338-47-6 2-(2-chloro-3-(hydroxymethyl)phenyl)ethanol 
• 1263265-86-6 3-(2-chloro-3-((4-(2-ethylthiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)methyl)phenethoxy)-N-cyclopentyl-N-(2,2-dimethoxyethyl)propanamide 
• 1263265-66-2 3-(2-chloro-3-((4-(2-ethylthiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)methyl)phenethoxy)propanoic acid 
• 1263265-65-1 tert-butyl 3-(2-chloro-3-((4-(2-ethylthiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)methyl)phenethoxy)propanoate 
• 1263265-64-0 (9-(2-chloro-3-(2-hydroxyethyl)benzyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(2-ethylthiazol-4-yl)methanone 
• 1179338-48-7 2-chloro-3-(2-hydroxyethyl)benzaldehyde 
• 1179338-45-4 2-chloro-3-(cyanomethyl)benzoic acid 

Relevant academic research and scientific papers

Compounds - 801

Spirocyclic amide derivatives of formula I wherein ArCH2CH2NH— represents a β-adrenoceptor binding group, processes for their preparation, pharmaceutical compositions containing them, a process for preparing such pharmaceutical compo

Design, synthesis and identification of novel colchicine-derived immunosuppressant

Synthesis and biological evaluation of various colchicine analogues through the mixed-lymphocyte reaction (MLR), lymphoproliferation, and inhibitory effects on the inflammatory genes are described. In addition, a new series of immunosuppressive agents developed on the structural basis of colchicine, as well as their structure-activity relationships is reported. The most potent analogue 20a exhibited an excellent immunosuppressive activity on in vivo skin-allograft model, which is comparable to that of cyclosporin A.

2,3,4-trinor-1,5-inter-meta-phenylene-prostacyclin compounds useful in inhibiting thrombocyte aggregation

The invention relates to new 2,3,4-trinor-1,5-inter-m-phenylene-PGI2 derivatives of the formula (I) STR1 wherein A stands for carboxy, cyano, tetrazolyl or --COOR3 or --CONR1 R2 ; R3 is C1-4 alkyl or an equivalent of a pharmacologically acceptable cation: R1 and R2 each stands for hydrogen, phenyl; C1-5 alkyl, optionally substituted by carboxy, hydroxy, phenyl or C2-5 alkoxycarbonyl; or C1-4 alkylsulfonyl; or R1 and R2 together form an α,ω-alkylene chain containing 3-6 carbon atoms; B stands for oxygen or methylene; Y is optionally bromo-substituted vinylene or a --C C-- group: R4 stands for hydrogen or tetrahydro-pyran-2-yl; R5 represents an alkyl group containing 5-9 carbon atoms, which can be optionally interrupted by one or more oxygen atom(s) or --CH=CH-- or --C C-- group(s) and/or optionally substituted by halogen; or a phenyoxymethyl group optionally substituted by halogen or trifluoromethyl; or an alkenoyloxymethyl group containing 3-5 carbon atoms; R6 is hydrogen or C1-4 alkyl; R7 stands for hydrogen, halogen, cyano, C1-4 alkyl or C1-4 alkoxy; R8 is hydrogen, halogen, cyano, nitro, hydroxy or C2-5 alkanoylamido; with the proviso that if R5 stands for an alkyl group containing 5-9 carbon atoms which is unsubstituted or not interrupted by an oxygen atom or a --CH=CH-- or --C C-- group; or a phenyoxymethyl group optionally substituted by halogen or trifluoromethyl, then either R7 or R8 is other than hydrogen, or A is other than carboxy or --COOR3 and a process for the preparation thereof. The new compounds of the Formula I exhibit prolonged cytoprotecting and aggregation inhibiting and a low hypotensive effect and are superior to prostacycline in the prolonged duration of their activity.